The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•26 February 2026•

1 min read

Vera Therapeutics Gets FDA Priority Review for Atacicept and Confirms Funding Through Launch

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

Key Facts

1The FDA granted priority review to the Biologics License Application (BLA) for atacicept for the treatment of IgA nephropathy (IgAN).

Vera Therapeutics (Nasdaq: VERA) announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its Biologics License Application (BLA) for atacicept. The drug is designed to treat IgA nephropathy (IgAN), following positive clinical data from the Phase 3 ORIGIN 3 study. The FDA has set a PDUFA action date for July 7, 2026, with a potential commercial launch anticipated in mid-2026. Alongside this regulatory milestone, the company reported its full-year 2025 financial results, highlighting a robust capital position. Vera Therapeutics confirmed that its current balance sheet is sufficient to fund operations well beyond the drug's approval and initial U.S. market entry. This financial stability, supported by recent equity and debt financing, ensures the company can meet its strategic commercialization goals.